)
Shares of Natco Pharma were trading higher by 4% at Rs 1,609, extending its previous day’s 2.5% gain on BSE, after the company announced that it has launched the first generic version of sofosbuvir in Nepal.
Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences, Inc., under its brand Sovaldi®. Natco markets generic sofosbuvir under its brand HEPCINAT, the company said in a press release.
Natco priced its generic medicine at an MRP of Rs 19,900 for a bottle of 28 tablets in Nepal.
The company said it hopes to launch HEPCINAT in India soon, subject to approval from the Drugs Controller General of India (DCGI).
The pharmaceutical company had recently signed a non-exclusive licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries, it added.
The stock opened at Rs 1,583 and hit a high of Rs 1,625, also its record high on BSE. Till 0930 hours, a combined 27,629 shares changed hands on the counter on BSE and NSE.
Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences, Inc., under its brand Sovaldi®. Natco markets generic sofosbuvir under its brand HEPCINAT, the company said in a press release.
Natco priced its generic medicine at an MRP of Rs 19,900 for a bottle of 28 tablets in Nepal.
The company said it hopes to launch HEPCINAT in India soon, subject to approval from the Drugs Controller General of India (DCGI).
The pharmaceutical company had recently signed a non-exclusive licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries, it added.
The stock opened at Rs 1,583 and hit a high of Rs 1,625, also its record high on BSE. Till 0930 hours, a combined 27,629 shares changed hands on the counter on BSE and NSE.
